Production and separation of 43 Sc for radiopharmaceutical purposes.

Autor: Domnanich KA; 1Laboratory of Radiochemistry, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland.; 2Department of Chemistry and Biochemistry, University of Bern, 3012 Bern, Switzerland., Eichler R; 1Laboratory of Radiochemistry, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland., Müller C; 3Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland.; 4Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zurich, Switzerland., Jordi S; 1Laboratory of Radiochemistry, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland.; 2Department of Chemistry and Biochemistry, University of Bern, 3012 Bern, Switzerland., Yakusheva V; 5GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany., Braccini S; 6Albert Einstein Center for Fundamental Physics (AEC), Laboratory for High Energy Physics (LHEP), University of Bern, 3012 Bern, Switzerland., Behe M; 3Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland., Schibli R; 3Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland.; 4Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zurich, Switzerland., Türler A; 2Department of Chemistry and Biochemistry, University of Bern, 3012 Bern, Switzerland., van der Meulen NP; 1Laboratory of Radiochemistry, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland.; 3Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland.
Jazyk: angličtina
Zdroj: EJNMMI radiopharmacy and chemistry [EJNMMI Radiopharm Chem] 2017; Vol. 2 (1), pp. 14. Date of Electronic Publication: 2017 Nov 25.
DOI: 10.1186/s41181-017-0033-9
Abstrakt: Background: The favorable decay properties of 43 Sc and 44 Sc for PET make them promising candidates for future applications in nuclear medicine. An advantage 43 Sc (T 1/2 = 3.89 h, Eβ + av = 476 keV [88%]) exhibits over 44 Sc, however, is the absence of co-emitted high energy γ-rays. While the production and application of 44 Sc has been comprehensively discussed, research concerning 43 Sc is still in its infancy. This study aimed at developing two different production routes for 43 Sc, based on proton irradiation of enriched 46 Ti and 43 Ca target material.
Results: 43 Sc was produced via the 46 Ti(p,α) 43 Sc and 43 Ca(p,n) 43 Sc nuclear reactions, yielding activities of up to 225 MBq and 480 MBq, respectively. 43 Sc was chemically separated from enriched metallic 46 Ti (97.0%) and 43 CaCO 3 (57.9%) targets, using extraction chromatography. In both cases, ~90% of the final activity was eluted in a small volume of 700 μL, thereby, making it suitable for direct radiolabeling. The prepared products were of high radionuclidic purity, i.e. 98.2% 43 Sc were achieved from the irradiation of 46 Ti, whereas the product isolated from irradiated 43 Ca consisted of 66.2% 43 Sc and 33.3% 44 Sc. A PET phantom study performed with 43 Sc, via both nuclear reactions, revealed slightly improved resolution over 44 Sc. In order to assess the chemical purity of the separated 43 Sc, radiolabeling experiments were performed with DOTANOC, attaining specific activities of 5-8 MBq/nmol, respectively, with a radiochemical yield of >96%.
Conclusions: It was determined that higher 43 Sc activities were accessible via the 43 Ca production route, with a comparatively less complex target preparation and separation procedure. The product isolated from irradiated 46 Ti, however, revealed purer 43 Sc with minor radionuclidic impurities. Based on the results obtained herein, the 43 Ca route features some advantages (such as higher yields and direct usage of the purchased target material) over the 46 Ti path when aiming at 43 Sc production on a routine basis.
Competing Interests: This article does not contain any studies with human participants performed by any of the authors. All applicable international, national, and/or institutional guidelines for the care and use of test animals were followed.The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Databáze: MEDLINE
Externí odkaz: